Stay updated with breaking news from Biologicals ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated Apr 17, 2021, 8:04 am IST Union minister Prakash Javadekar and Karnataka CM B.S. Yediyurappa tested positive on Friday India decided to import 50,000 metric tonnes of medical oxygen to reduce the shortage of supplies. PTI New Delhi: As the daily fresh Covid-19 cases went over 2.17 lakhs and the death toll reached 1,185, Prime Minister Narendra Modi on Friday chaired a comprehensive review meeting to ensure adequate medical grade oxygen supply in the country. The meeting took place a day after India decided to import 50,000 metric tonnes of medical oxygen to reduce the shortage of supplies. Union minister Prakash Javadekar and Karnataka CM B.S. Yediyurappa were, meanwhile, among those who tested positive on Friday. Mr Yediyurappa has in fact tested positive for the second time in eight months and has been hospitalised. ....
Modi reviews oxygen crisis as cases touch new high: 21.7 lakh asianage.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asianage.com Daily Mail and Mail on Sunday newspapers.
India Scrambles to Stem COVID-19 Tide as New Cases Continue to Surge India s response to its new COVID-19 epidemic is going through an inflexion. Passengers at a bus terminal, amid the ongoing surge in coronavirus cases, in Kanpur, Friday, April 16, 2021. Photo: PTI Bengaluru: India’s response to its new COVID-19 epidemic is going through an inflexion. It was most prominent when the government stopped sharing its daily bulletin of adverse events following immunisation. Next, Brazil’s vaccine regulator Anvisa said Bharat Biotech wasn’t following good manufacturing practices to make Covaxin, the ‘Made in India’ vaccine in the country’s two-vaccine inoculation campaign. Supporters of the government rose in its defence but the presence of problems was unmistakable, calling into question why India’s vaccine regulator didn’t notice them. ....
India Going Through a Spate of U-Turns in Scramble To Stem COVID-19 Tide 17/04/2021 Bengaluru: India’s response to its new COVID-19 epidemic is going through an inflexion. It was most prominent when the government stopped sharing its daily bulletin of adverse events following immunisation. Next, Brazil’s vaccine regulator Anvisa said Bharat Biotech wasn’t following good manufacturing practices to make Covaxin, the ‘Made in India’ vaccine in the country’s two-vaccine inoculation campaign. Supporters of the government rose in its defence but the presence of problems was unmistakable, calling into question why India’s vaccine regulator didn’t notice them. ....
Govt moves to step-up Covaxin production April 16, 2021 × Ropes in 3 govt units, funds upgrade of Bharat Bio facility to raise monthly output to 10 cr doses by Sept The Government has unveiled a plan to expand the manufacture of indigenous vaccine, Covaxin. The aim is to make 10 crore doses a month, by September. The plan involves upgrading Hyderabad-based Bharat Biotech Ltd, which produces Covaxin, besides building-up the production capacities of public sector manufacturers Haffkine Biopharmaceutical Corp, Indian Immunologicals Ltd, and Bharat Immunologicals & Biologicals Corporation with infrastructure and technology. The current production capacity will be doubled by May-June and then increased 6-7 fold by July-August. Thta is, production will be stepped up from 1 crore doses in April to 6-7 crore vials per month in July-August. It is likely to reach nearly 10 crore doses per month by September under the government’s Mission Covid Suraksha, the ....